Safeguard Scientifics, Inc. (NYSE:SFE) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price target of $20.00 for the company and are anticipating that the company will post ($1.05) EPS for the current quarter, according to Zacks. Zacks has also given Safeguard Scientifics an industry rank of 167 out of 265 based on the ratings given to its competitors.
Several equities analysts have recently issued reports on SFE shares. ValuEngine upgraded Safeguard Scientifics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research lowered Safeguard Scientifics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, BidaskClub lowered Safeguard Scientifics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th.
Safeguard Scientifics (SFE) opened at $14.15 on Friday. Safeguard Scientifics has a 52 week low of $10.60 and a 52 week high of $14.40. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 1.03.
Safeguard Scientifics (NYSE:SFE) last posted its quarterly earnings data on Thursday, October 26th. The asset manager reported ($0.91) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.11) by $0.20. During the same period in the prior year, the business posted ($1.18) EPS. equities analysts predict that Safeguard Scientifics will post -4.47 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Safeguard Scientifics by 5.2% in the 1st quarter. Wells Fargo & Company MN now owns 15,951 shares of the asset manager’s stock valued at $203,000 after purchasing an additional 791 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Safeguard Scientifics by 12.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 15,336 shares of the asset manager’s stock valued at $195,000 after purchasing an additional 1,754 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Safeguard Scientifics by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 828,897 shares of the asset manager’s stock valued at $10,528,000 after purchasing an additional 15,086 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Safeguard Scientifics by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 146,721 shares of the asset manager’s stock valued at $1,863,000 after purchasing an additional 6,742 shares during the last quarter. Finally, Salzhauer Michael increased its stake in shares of Safeguard Scientifics by 73.4% in the 2nd quarter. Salzhauer Michael now owns 18,900 shares of the asset manager’s stock valued at $225,000 after purchasing an additional 8,000 shares during the last quarter. Institutional investors own 77.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks: Safeguard Scientifics, Inc. (SFE) Receives Average Recommendation of “Strong Buy” from Analysts” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.com-unik.info/2017/11/06/zacks-safeguard-scientifics-inc-sfe-receives-average-recommendation-of-strong-buy-from-analysts.html.
About Safeguard Scientifics
Safeguard Scientifics, Inc is engaged in providing capital to technology companies within the fields of healthcare, financial services and digital media. The Company holds interest in companies, which it refers to as partner companies. As of December 31, 2016, the Company held interests in 29 non-consolidated partner companies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Safeguard Scientifics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Safeguard Scientifics Inc. and related companies.